4-bromo-7-(trifluoromethoxy)benzo[d]isoxazol-3-ylamine | 819058-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: 4-bromo-7-(trifluoromethoxy)benzo[d]isoxazol-3-ylamine
• 英文别名: 4-bromo-7-(trifluoromethoxy)-1,2-benzoxazol-3-amine
• CAS: 819058-18-9
• 化学式: C₈H₄BrF₃N₂O₂
• 分子量: 297.031
• InChiKey: DIXLJBZLCZBNCY-UHFFFAOYSA-N

物化性质

• 沸点：
  349.5±37.0 °C(Predicted)
• 密度：
  1.874±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  61.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-bromo-7-(trifluoromethoxy)benzo[d]isoxazol-3-ylamine 、 4-氨基苯硼酸频哪醇酯 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 生成 4-(4-aminophenyl)-7-(trifluoromethoxy)benzo[d]isoxazol-3-ylamine
  参考文献：
  名称：

  3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases

  摘要：

  A series of benzoisoxazoles and benzoisothiazoles have been synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). Structure-activity relationship studies led to the identification of 3-amino benzo[d]isoxazoles, incorporating a N,N'-diphenyl urea moiety of the 4-position that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor families of RTKs. Within this series, orally bioavailable compounds possessing promising pharmacokinetic profiles were identified, and a number of compounds demonstrated in vivo efficacy in models of VEGF-stimulated vascular permeability and tumor growth. In particular, compound 50 exhibited an ED50 of 2.0 mg/kg in the VEGF-stimulated uterine edema model and 81% inhibition in the human fibrosarcoma (HT1080) tumor growth model when given orally at a dose of 10 mg/kg/day.

  DOI：

  10.1021/jm701096v
• 作为产物：
  描述：

  6-Bromo-2-fluoro-3-(trifluoromethoxy)benzonitrile 在 potassium tert-butylate 、 丙酮肟 作用下， 以 四氢呋喃 为溶剂， 反应 10.5h， 以32%的产率得到4-bromo-7-(trifluoromethoxy)benzo[d]isoxazol-3-ylamine
  参考文献：
  名称：

  3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases

  摘要：

  A series of benzoisoxazoles and benzoisothiazoles have been synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). Structure-activity relationship studies led to the identification of 3-amino benzo[d]isoxazoles, incorporating a N,N'-diphenyl urea moiety of the 4-position that potently inhibited both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor families of RTKs. Within this series, orally bioavailable compounds possessing promising pharmacokinetic profiles were identified, and a number of compounds demonstrated in vivo efficacy in models of VEGF-stimulated vascular permeability and tumor growth. In particular, compound 50 exhibited an ED50 of 2.0 mg/kg in the VEGF-stimulated uterine edema model and 81% inhibition in the human fibrosarcoma (HT1080) tumor growth model when given orally at a dose of 10 mg/kg/day.

  DOI：

  10.1021/jm701096v

文献信息

• Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
  申请人：Dai Yujia

  公开号：US20050020603A1

  公开（公告）日：2005-01-27

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白酪氨酸激酶很有用。本发明还揭示了制备这些化合物的方法，包含这些化合物的组合物以及使用这些化合物的治疗方法。
• INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS
  申请人：Dai Yujia

  公开号：US20080076767A1

  公开（公告）日：2008-03-27

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法，含有这些化合物的组合物以及使用这些化合物的治疗方法。
• US7297709B2
  申请人：——

  公开号：US7297709B2

  公开（公告）日：2007-11-20
• US7598283B2
  申请人：——

  公开号：US7598283B2

  公开（公告）日：2009-10-06
• US8063091B2
  申请人：——

  公开号：US8063091B2

  公开（公告）日：2011-11-22